Phase 2/3-Ready Orphan Disease Program Complements Company’s Existing Late-Stage Rare Disease Pipeline PRINCETON, N.J., May 1, 2023 /PRNewswire/ — Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing…